Literature DB >> 2141037

Double-negative (CD4- CD8-) T cells with an alpha/beta T cell receptor. Non-MHC-restricted cytolytic activity and lymphokine production.

E G Brooks1, D P Wirt, R M Goldblum, S Vaidya, M T Asuncion, J C Patterson, C F Ware, G R Klimpel.   

Abstract

T cell lines with a novel phenotype (CD3+ TCR-alpha/beta+ CD4- CD8-) were developed from the peripheral blood of a patient with a combined immunodeficiency and tissue injury resembling graft-vs-host disease. One of these IL-2-dependent T cell lines demonstrated non-MHC-restricted cytolytic function against tumor targets, syngeneic and allogeneic fibroblasts, and PHA blasts from allogeneic donors. The other cell line only became cytotoxic in the presence of lectin or anti-CD3 antibody. The two cell lines also differed in their expression of the T-200 gene products CD45RO (gp180) and CD45RA (gp220). Both cell lines produced tumor necrosis factor-alpha and -beta and IFN-gamma activity when activated with mitogens or PMA and IL-1. The in vitro functions of these T-cell lines suggest a potential role for alpha/beta double-negative T lymphocytes in tissue injury resembling graft-vs-host disease.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2141037

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  10 in total

1.  Mechanism of human immunodeficiency virus type 1 localization in CD4-negative thymocytes: differentiation from a CD4-positive precursor allows productive infection.

Authors:  S G Kitchen; C H Uittenbogaart; J A Zack
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

2.  Depletion of T-cell subpopulations results in exacerbation of myocarditis and parasitism in experimental Chagas' disease.

Authors:  R L Tarleton; J Sun; L Zhang; M Postan
Journal:  Infect Immun       Date:  1994-05       Impact factor: 3.441

3.  Induction of hypertension and peripheral inflammation by reduction of extracellular superoxide dismutase in the central nervous system.

Authors:  Heinrich E Lob; Paul J Marvar; Tomasz J Guzik; Shraya Sharma; Louise A McCann; Cornelia Weyand; Frank J Gordon; David G Harrison
Journal:  Hypertension       Date:  2009-12-14       Impact factor: 10.190

4.  A novel lymphoproliferative/autoimmune syndrome resembling murine lpr/gld disease.

Authors:  M C Sneller; S E Straus; E S Jaffe; J S Jaffe; T A Fleisher; M Stetler-Stevenson; W Strober
Journal:  J Clin Invest       Date:  1992-08       Impact factor: 14.808

5.  Human T-cell receptor (TCR) alpha/beta + CD4-CD8- T cells express oligoclonal TCRs, share junctional motifs across TCR V beta-gene families, and phenotypically resemble memory T cells.

Authors:  E G Brooks; S P Balk; K Aupeix; M Colonna; J L Strominger; V Groh-Spies
Journal:  Proc Natl Acad Sci U S A       Date:  1993-12-15       Impact factor: 11.205

6.  Definition of unique traits of human CD4-CD8- alpha beta T cells.

Authors:  J G Murison; S Quaratino; M Kahan; A Verhoef; M Londei
Journal:  Clin Exp Immunol       Date:  1993-09       Impact factor: 4.330

7.  Isolation and characterization of a low metastatic variant from EL-4 mouse T-lymphoma.

Authors:  T Ota; M Tanino; H Kohno; H Funamoto; S Odashima
Journal:  Clin Exp Metastasis       Date:  1992-09       Impact factor: 5.150

8.  Human double-negative (CD4-CD8-) T cells bearing alpha beta T cell receptor possess both helper and cytotoxic activities.

Authors:  M Matsumoto; M Yasukawa; A Inatsuki; Y Kobayashi
Journal:  Clin Exp Immunol       Date:  1991-09       Impact factor: 4.330

9.  Cutaneous lymphoproliferation and lymphomas in interleukin 7 transgenic mice.

Authors:  B E Rich; J Campos-Torres; R I Tepper; R W Moreadith; P Leder
Journal:  J Exp Med       Date:  1993-02-01       Impact factor: 14.307

10.  Analysis of T cell antigen receptor (TCR) expression by human peripheral blood CD4-8- alpha/beta T cells demonstrates preferential use of several V beta genes and an invariant TCR alpha chain.

Authors:  S Porcelli; C E Yockey; M B Brenner; S P Balk
Journal:  J Exp Med       Date:  1993-07-01       Impact factor: 14.307

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.